Literature DB >> 6225471

Somatomedins in Down's syndrome.

V R Sara, K H Gustavson, G Annerén, K Hall, L Wetterberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6225471

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  5 in total

1.  Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development.

Authors:  G Annerén; T Tuvemo; C Carlsson-Skwirut; T Lönnerholm; P Bang; V R Sara; J Gustafsson
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

2.  Growth charts for Down's syndrome from birth to 18 years of age.

Authors:  A Myrelid; J Gustafsson; B Ollars; G Annerén
Journal:  Arch Dis Child       Date:  2002-08       Impact factor: 3.791

Review 3.  Endocrine and musculoskeletal abnormalities in patients with Down syndrome.

Authors:  Yousra Hawli; Mona Nasrallah; Ghada El-Hajj Fuleihan
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

4.  Assessment of growth hormone insulin like growth factor-I axis in Down's syndrome.

Authors:  A Barreca; A Rasore Quartino; M S Acutis; P Ponzani; G Damonte; E Miani; V Balestra; G Giordano; F Minuto
Journal:  J Endocrinol Invest       Date:  1994-06       Impact factor: 4.256

5.  Growth and somatomedin responses to growth hormone in Down's syndrome.

Authors:  G Annerén; V R Sara; K Hall; T Tuvemo
Journal:  Arch Dis Child       Date:  1986-01       Impact factor: 3.791
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.